Engineered immune cells take on tough blood cancers
NCT ID NCT07162571
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study tests a new treatment using a patient's own immune cells, modified to target and kill cancer cells in adults with leukemia or lymphoma that has come back or not responded to standard therapy. The trial has two phases: first to check safety, then to see how well the treatment works. About 17 participants will receive the therapy and be monitored for side effects and cancer response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Dermatology
Minsk, 220087, Belarus
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.